Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

被引：906
作者：
Baselga, Jose [1 ]
Swain, Sandra M. [2 ]
机构：
[1] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol, Barcelona 08035, Spain
[2] Washington Hosp Ctr, Washington Canc Inst, Washington, DC 20010 USA
来源：
NATURE REVIEWS CANCER | 2009年 / 9卷 / 07期
关键词：
EPIDERMAL-GROWTH-FACTOR; HUMAN-BREAST-CANCER; C-ERBB-3 PROTEIN EXPRESSION; TYROSINE KINASE INHIBITOR; FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; LUNG-CANCER; PHASE-II; PHOSPHATIDYLINOSITOL; 3-KINASE; DIMERIZATION INHIBITOR;
D O I：
10.1038/nrc2656
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb) family plays a crucial part in the development and evolution of cancer. Inhibiting the signalling activity of individual receptors in this family has advanced the treatment of a range of human cancers. In this Review we re-evaluate the role of two important family members, ERBB2 (also known as HER2) and ERBB3 (also known as HER3), and explore the mechanisms of action and preclinical and clinical data for new therapies that target signalling through these pivotal receptors. These new therapies include tyrosine kinase inhibitors, antibody-chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2-ERBB3 dimers.
引用
收藏
页码：463 / 475
页数：13
相关论文
共 145 条
  • [1] Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
    Agus, DB
    Gordon, MS
    Taylor, C
    Natale, RB
    Karlan, B
    Mendelson, DS
    Press, MF
    Allison, DE
    Sliwkowski, MX
    Lieberman, G
    Kelsey, SM
    Fyfe, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2534 - 2543
  • [2] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
    Agus, DB
    Akita, RW
    Fox, WD
    Lewis, GD
    Higgins, B
    Pisacane, PI
    Lofgren, JA
    Tindell, C
    Evans, DP
    Maiese, K
    Scher, HI
    Sliwkowski, MX
    [J]. CANCER CELL, 2002, 2 (02) : 127 - 137
  • [3] AMLER L, 2008, P 99 ANN M AM ASS CA
  • [4] A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer
    Arteaga, Carlos L.
    O'Neill, Anne
    Moulder, Stacy L.
    Pins, Michael
    Sparano, Joseph A.
    Sledge, George W.
    Davidson, Nancy E.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6277 - 6283
  • [5] Atlas E, 2003, MOL CANCER RES, V1, P165
  • [6] Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
    Austin, CD
    De Mazière, AM
    Pisacane, PI
    van Dijk, SM
    Eigenbrot, C
    Sliwkowski, MX
    Klumperman, J
    Scheller, RH
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (12) : 5268 - 5282
  • [7] A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization
    Baselga, J
    [J]. CANCER CELL, 2002, 2 (02) : 93 - 95
  • [8] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast
    Baselga, J
    Tripathy, D
    Mendelsohn, J
    Baughman, S
    Benz, CC
    Dantis, L
    Sklarin, NT
    Seidman, AD
    Hudis, CA
    Moore, J
    Rosen, PP
    Twaddell, T
    Henderson, IC
    Norton, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 737 - 744
  • [9] Baselga J, 1998, CANCER RES, V58, P2825
  • [10] Baselga J, 2007, J CLIN ONCOL, V25, P4516, DOI 10.1200/JCO.2007.12.8900
12345678910